Robert E MacLaren
Overview
Explore the profile of Robert E MacLaren including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
332
Citations
6241
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Forte G, Ahmed R, MacLaren R, Jolly J, Taylor L
Clin Exp Optom
. 2025 Feb;
:1-7.
PMID: 40010402
Clinical Relevance: Low-luminance visual acuity and low-luminance deficit (standard visual acuity minus low-luminance visual acuity) are gaining popularity as outcome measures in clinical trials for retinal disease, demonstrating capability to...
2.
Fry L, Major L, Salman A, McDermott L, Yang J, King A, et al.
Commun Biol
. 2025 Feb;
8(1):200.
PMID: 39922978
CRISPR-Cas13 systems have therapeutic promise for the precise correction of point mutations in RNA. Using adenosine deaminase acting on RNA (ADAR) effectors, A-I base conversions can be targeted using guide...
3.
Elsayed M, Abdalla Elsayed M, Cehajic Kapetanovic J, Cehajic-Kepetanovic J, MacLaren R
Expert Opin Biol Ther
. 2025 Feb;
25(3):257-263.
PMID: 39893699
Introduction: Choroideremia is a rare disease with a significant disease burden. Gene-supplementation methods for choroideremia gene therapy have been the most successful form of gene therapy thus far. Areas Covered:...
4.
Salman A, Amoros A, Bolinches-Amoros A, Storm T, Moralli D, Bryika P, et al.
J Cell Physiol
. 2024 Nov;
240(1):e31482.
PMID: 39605294
Cell replacement therapies for ocular diseases characterised by photoreceptors degeneration are challenging due to poor primary cell survival in culture. A stable retinal cell source to replace lost photoreceptors holds...
5.
Poli F, MacLaren R, Cehajic-Kapetanovic J
Genes (Basel)
. 2024 Nov;
15(11).
PMID: 39596671
Background: Choroideremia is a monogenic inherited retinal dystrophy that manifests in males with night blindness, progressive loss of peripheral vision, and ultimately profound sight loss, commonly by middle age. It...
6.
MacLaren R, Duncan J, Fischer M, Lam B, Meunier I, Pennesi M, et al.
Ophthalmol Sci
. 2024 Nov;
5(1):100595.
PMID: 39493534
Objective: To improve the understanding of the natural disease progression of ()associated X-linked retinitis pigmentosa (XLRP). Design: A multicenter, prospective, observational natural history study over 24 months. Participants: Male participants...
7.
Borchert G, Kiire C, Stone N, Akil H, Gkika T, Fischer M, et al.
Eye (Lond)
. 2024 Oct;
38(18):3569-3577.
PMID: 39394370
Background: Landmark studies reported on faricimab efficacy and safety predominantly in treatment naïve patients, but outcomes following switch from other anti-VEGF therapies are lacking. We evaluated patients switched to faricimab...
8.
Taylor L, Josan A, Adeyoju D, Jolly J, MacLaren R
Transl Vis Sci Technol
. 2024 Sep;
13(9):29.
PMID: 39348136
Purpose: Choroideremia is an X-linked outer retinal degeneration. Early symptoms include nyctalopia and progressive visual field loss, but visual acuity is preserved until late disease stages. Dark-adapted two-color fundus-controlled perimetry...
9.
Narayan A, Taylor L, Sperring S, Shanks M, Clouston P, MacLaren R, et al.
Ophthalmic Genet
. 2024 Sep;
45(6):668-675.
PMID: 39297444
Background: Danon disease is a rare, multisystemic X-linked dominant disorder caused by variants in the gene. It can be associated with retinal degeneration, but this is not well characterized. Here...
10.
Christou E, Josan A, Cehajic-Kapetanovic J, MacLaren R
Transl Vis Sci Technol
. 2024 Sep;
13(9):18.
PMID: 39287586
Purpose: Clinical trials for X-linked retinitis pigmentosa (RP) often assess retinal structure using optical coherence tomography (OCT) and function using microperimetry to evaluate initial eligibility and endpoints. Therefore, we seek...